Journal of postgraduate medicine最新文献

筛选

英文中文

Chronic thromboembolic pulmonary hypertension - Time is of the essence. 慢性血栓栓塞性肺动脉高压——时间至关重要。

Journal of postgraduate medicine Pub Date : 2023-10-01 DOI: 10.4103/jpgm.jpgm_707_23

V Taskar

引用次数: 0

How often are heart diseases correctly diagnosed antemortem in children with fatal illnesses? A retrospective review of medical and autopsy records. 患有致命疾病的儿童死前多久能正确诊断出心脏病？对医疗和尸检记录的回顾性审查。

Journal of postgraduate medicine Pub Date : 2023-10-01 DOI: 10.4103/jpgm.jpgm_608_23

S Karande, P Vaideeswar, T More

引用次数: 0

Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics? 生物仿制药的药物警戒-为什么它与仿制药和创新生物制品不同？

Journal of postgraduate medicine Pub Date : 2019-10-01 DOI: 10.4103/jpgm.JPGM_109_19

B Oza, S Radhakrishna, P Pipalava, V Jose

{"title":"Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?","authors":"B Oza, S Radhakrishna, P Pipalava, V Jose","doi":"10.4103/jpgm.JPGM_109_19","DOIUrl":"https://doi.org/10.4103/jpgm.JPGM_109_19","url":null,"abstract":"<p><p>Biosimilars are being marketed in India since 2000. Like biologics, biosimilars have a large size, complex structure, and complicated manufacturing process, and they are produced in a living organism. It requires specialized delivery devices for administration and needs tighter temperature control to prevent degradation. As biosimilar development follows abbreviated pathway, adverse events (AEs) previously unknown during a clinical trial may be detected postmarketing. In India, the awareness on pharmacovigilance has increased significantly after implementation of the pharmacovigilance guidance in January 2018. However, biologics require tighter monitoring to ensure their safety and efficacy. This review article discusses the importance of pharmacovigilance for biosimilars, how it is different from generics, and provides recommendations to sensitize clinicians and researchers about the requirement of a different approach to improve pharmacovigilance for biosimilars. Pharmacovigilance for biosimilars is as important as it is for innovator biologics and more important than that for generics.</p>","PeriodicalId":94105,"journal":{"name":"Journal of postgraduate medicine","volume":"65 4","pages":"227-232"},"PeriodicalIF":0.0,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41224165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

首页上一页